KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $338.3 million.

  • Ionis Pharmaceuticals' Cash & Equivalents rose 111.65% to $338.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.3 million, marking a year-over-year increase of 111.65%. This contributed to the annual value of $242.1 million for FY2024, which is 3936.95% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Cash & Equivalents is $338.3 million, which was up 111.65% from $297.3 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Cash & Equivalents ranged from a high of $869.2 million in Q4 2021 and a low of $242.1 million during Q4 2024
  • Over the past 5 years, Ionis Pharmaceuticals' median Cash & Equivalents value was $348.9 million (recorded in 2024), while the average stood at $407.5 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Cash & Equivalents soared by 11857.42% in 2021, and later plummeted by 6819.2% in 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' Cash & Equivalents (Quarter) stood at $869.2 million in 2021, then tumbled by 68.19% to $276.5 million in 2022, then surged by 44.41% to $399.3 million in 2023, then crashed by 39.37% to $242.1 million in 2024, then skyrocketed by 39.77% to $338.3 million in 2025.
  • Its last three reported values are $338.3 million in Q3 2025, $297.3 million for Q2 2025, and $264.2 million during Q1 2025.